Human EPO R/Erythropoietin R Protein

Cat. No.   EPO-HM50R

KACTUS

Description

Source	Recombinant Human EPO R/Erythropoietin R Protein is expressed from HEK293 with hFc tag and Avi tag at the C-terminus.
	It contains Ala25-Pro250.
Accession	P19235-1
Molecular Weight	The protein has a predicted MW of 52.58 kDa. Due to glycosylation, the protein migrates to 55-70 kDa based on Bis-Tris PAGE result.
Endotoxin	Less than 1EU per µg by the LAL method.
Purity	> 95% as determined by Bis-Tris PAGE
	> 95% as determined by HPLC

Formulation and Storage

|	
Formulation	Lyophilized from 0.22 µm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution	Centrifuge the tube before opening. Reconstituting to a concentration more than 100 µg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage	-20 to -80°C for 12 months as supplied from date of receipt.-80°C for 3 months after reconstitution.Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Background

The erythropoietin (epo) receptor is a member of the cytokine receptor family. It is expressed almost exclusively on erythroid precursor cells and controls the development of red blood cells. The epo receptor has no intrinsic kinase activity, but binds intracellular tyrosine kinases to elicit its signals. Alterations in the transmission of the signalling cascade lead to clinically abnormal red blood cell production.

Assay Data

Bis-Tris PAGE

Human EPO R on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC

Assay Data

The purity of Human EPO R is greater than 95% as determined by SEC-HPLC.

ELISA Data

Human EPO R, hFc Tag ELISA
0.2μg Human EPO, No Tag Per Well

Immobilized Human EPO, No Tag at 2μg/ml (100μl/well) on the plate. Dose response curve for Human EPO R, hFc Tag with the EC50 of 35.5ng/ml determined by ELISA.